Decoy Therapeutics
DCOY
2 hedge funds and large institutions have $13.4K invested in Decoy Therapeutics in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
77% more capital invested
Capital invested by funds: $7.55K → $13.4K (+$5.81K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.59K |
| 2 |
Citigroup
New York
|
-$2.32K |
DCOY Hedge Fund Activity: Q4 2024 in Review
2 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2024, worth a combined $13.4K — up 77% from $7.55K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DCOY and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $10.4K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $4.59K sold.
- 2 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2024, down from 4 in Q3 2024.
- Funds reported $13.4K of Decoy Therapeutics stock for Q4 2024, up 77% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q4 2024 and 2 closed out, a net change of -2 holders.
- The largest Decoy Therapeutics buyer in Q4 2024 was UBS Group, an estimated $10.4K added.
- The largest Decoy Therapeutics seller in Q4 2024 was Tower Research Capital (TRC), an estimated $4.59K sold.
Based on aggregated 13F filings for Q4 2024.